DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Content Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds approved or listed by major regulatory agencies, supporting rapid drug repositioning and pharmacological target identification [ApexBio Product Page]. Each compound is provided as a 10 mM pre-dissolved solution in DMSO, stable for up to 24 months at -80°C. The library includes drugs with well-characterized mechanisms, such as doxorubicin and metformin, and is validated for high-throughput screening (HTS) and high-content screening (HCS) platforms. Its use in antiviral screening against SARS-CoV-2 has identified specific entry inhibitors, demonstrating translational impact (Chan et al., 2021). The DiscoveryProbe™ FDA-approved Drug Library is a foundational tool for oncology, neurodegenerative disease, and signaling pathway research, as highlighted by recent translational studies [EpigeneticsDomain].

Biological Rationale

Drug repositioning leverages existing pharmacological agents to identify new indications, reducing time and cost compared to de novo development (Chan et al., 2021). FDA-approved compound libraries enable systematic screening for activity against emerging targets, bypassing early-stage safety profiling. The DiscoveryProbe™ FDA-approved Drug Library brings together drugs affecting diverse mechanisms, including receptor modulation, enzyme inhibition, ion channel regulation, and signal pathway interference. These mechanisms are central to pathologies such as cancer, infectious diseases, and neurodegeneration. Screening with clinically validated molecules increases translational potential and facilitates rapid integration into clinical pipelines. The broad regulatory coverage (FDA, EMA, HMA, CFDA, PMDA) ensures global relevance for therapeutic discovery.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound collection encompasses drugs acting on a diversity of molecular targets:

• Receptor agonists/antagonists (e.g., beta-blockers, opioid antagonists)
• Enzyme inhibitors (e.g., kinase, protease, and HDAC inhibitors)
• Ion channel modulators (e.g., calcium, sodium, and potassium channel blockers)
• Signal pathway regulators (e.g., mTOR, MAPK, and PI3K pathway modulators)

These mechanisms have been validated in preclinical and clinical contexts, facilitating interrogation of cellular signaling, disease models, and pharmacological pathways. Notably, the library was instrumental in identifying 'kite-shaped' molecules that block SARS-CoV-2 entry at a post-attachment step, a conserved viral process (Chan et al., 2021). Such findings demonstrate the library's utility for both mechanistic studies and translational screening.

Evidence & Benchmarks

• Screening of 2,320 FDA-approved compounds identified multiple molecules that inhibit SARS-CoV-2 entry in vitro with IC₅₀ values of 2–5 μM in human cell lines (Chan et al., 2021, https://doi.org/10.3390/v13112306).
• Compounds are supplied as 10 mM DMSO solutions, stable for 12 months at -20°C and 24 months at -80°C, ensuring consistent performance across screening campaigns (ApexBio).
• The library includes drugs covering all major therapeutic classes, enabling systematic evaluation for oncology, infectious, and neurodegenerative disease models (EpigeneticsDomain).
• High-throughput and high-content screening protocols using the L1021 kit have been validated in both academic and industry laboratories (2xTAqPC).
• Integration with mechanistic studies of HDAC6 and related targets has accelerated translational workflows (HDAC4.com).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a broad range of applications:

• Drug repositioning for new disease indications
• Pharmacological target identification in cancer, neurodegenerative, and infectious disease research
• High-throughput and high-content screening for pathway interrogation
• Validation of disease models using clinically relevant compounds

For a deeper exploration of how this library streamlines drug repositioning and target identification, see this recent overview, which this article extends by focusing on regulatory diversity and antiviral screening benchmarks.

Integration with structural biology and signal pathway mapping distinguishes this resource from conventional collections (GSK690693.com); here, we update with specific SARS-CoV-2 entry inhibitor data.

Common Pitfalls or Misconceptions

• The library is not a replacement for primary high-throughput libraries of novel chemical matter; it contains only approved or listed drugs.
• Compounds may not inhibit every target; absence of activity does not preclude potential for structurally related molecules.
• Results from in vitro screens using the library may not translate directly to clinical efficacy due to differences in pharmacokinetics and exposure.
• Some compounds have restricted therapeutic windows; observed activity may be limited by cytotoxicity in certain cell types.
• The library is not intended for direct in vivo administration; it is formulated for research use only at specified concentrations and vehicles.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is formatted for immediate integration into automated screening platforms. Compounds are delivered as 10 mM DMSO solutions in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes. Storage at -20°C (up to 12 months) or -80°C (up to 24 months) maintains compound integrity. Shipping is performed on blue ice for evaluation sizes, and at room temperature or blue ice for larger kits. Screening protocols typically use final compound concentrations of 1–10 μM, adjusted for assay type. The library is suitable for cell-based, biochemical, and phenotypic assays. Data integration with pathway, target, and chemoinformatic databases is supported by standardized compound annotations and regulatory metadata.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a rigorously curated, ready-to-screen resource that accelerates drug repositioning, target identification, and mechanistic research across biomedical domains. Its proven success in identifying SARS-CoV-2 entry inhibitors highlights its translational value (Chan et al., 2021). By combining regulatory breadth, mechanistic diversity, and robust format, this FDA-approved bioactive compound library remains a first-line choice for high-throughput and high-content screening applications. For further insights on translational acceleration in oncology using this library, see this HDAC-centric analysis, which this article updates with broader screening and workflow integration benchmarks.

For full technical specifications, refer to the official product page: DiscoveryProbe™ FDA-approved Drug Library.